NCT05517083Completed
Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer
Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Advanced Non-small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 20 Aug 2025
Brief summary (registry, in English)
The purpose of this study is to evaluate the relevance of intratumoral washing for detection of EGFR mutation (including T790M positivity).
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 41 (actual)
- First submitted
- 30 Jul 2022
- Start date
- 1 Apr 2022
- Primary completion date
- 30 Sept 2023
- Lead sponsor
- Pusan National University Hospital
- Diseases
- Lung cancer
- NCT number
- NCT05517083
What you commit to
- Study type: Interventional
- Participants enrolled: 41
- From 1 Apr 2022 to the primary completion date, 30 Sept 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Patients who are unable to undergo liquid biopsy (plasma) and tissue biopsy for EGFR mutation based on the investigator's judgement
Other
- Patients who withdraw informed consent
Who the study is looking for
- Age ≥ 20 years
- Obtained written informed consent
- Patients diagnosed with NSCLC by histology or cytology and inoperable stage IV at the time of study enrollment
- Patients with the following EGFR gene mutations: E19Del, L858R alone or concurrent rare EGFR gene mutations (T790M, G719X, exon 20 insertion, S768I)
- Patients previously treated with EGFR-TKIs such as gefitinib, erlotinib, afatinib, dacomitinib as first line therapy
- Patients who had shown clinical benefits (CR, PR, SD) from EGFR-TKIs and had been confirmed PD on those therapy according to RECIST v 1.1.
- Patients who underwent liquid biopsy (plasma) for EGFR mutation at the time of PD on EGFR-TKIs
- Patients who plan to undergo tissue biopsy for EGFR mutation at the time of PD on EGFR-TKIs
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pusan National University Hospital Coordinator of this site? Confirm its status | Busan | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.